1-4 of 4
Michelle Rudek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS).

Nilofer Azad, Douglas Ball, Steven Sherman, Michelle Rudek, Gerald Falchook, Barry Nelkin, Filip Janku, Nicholas Papadopoulos, Ashley O'Conner, Shabina Ahmed, Breelyn Wilky, Susan Markus, Jing Gong, David Cosgrove, Marianna Zahurak, Ralph Zinner, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B279.
https://doi.org/10.1158/1535-7163.TARG-13-B279
Published: 01 November 2013
View article titled, Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS).
Journal Articles

Abstract B74: A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors.

Breelyn A. Wilky, Michelle Rudek, Daniel Laheru, David Cosgrove, Ross Donehower, Barry Nelkin, Douglas Ball, L. Austin Doyle, Helen Chen, Xiaobu Ye, Nilofer Azad
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B74.
https://doi.org/10.1158/1535-7163.TARG-13-B74
Published: 01 November 2013
View article titled, Abstract B74: A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors.
Journal Articles

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

Hans J. Hammers, Henk M. Verheul, Brenda Salumbides, Rajni Sharma, Michelle Rudek, Janneke Jaspers, Preeti Shah, Leigh Ellis, Li Shen, Silvia Paesante, Karl Dykema, Kyle Furge, Bin T. Teh, George Netto, Roberto Pili
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1525–1535.
https://doi.org/10.1158/1535-7163.MCT-09-1106
Published: 09 June 2010
View article titled, Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
Open the PDF for Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study in another window
Journal Articles

Abstract C246: nab®‐paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models

Anirban Maitra, N.V. Rajeshkumar, Michelle Rudek, Ignacio Garrido‐Laguna, Daniel Laheru, Jose Iglesias, Neil Desai, Daniel D. Von Hoff, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C246.
https://doi.org/10.1158/1535-7163.TARG-09-C246
Published: 10 December 2009
View article titled, Abstract C246: nab®‐paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models